Archive for the ‘misconduct investigations’ Category
Brigham and Women’s Hospital and its parent healthcare network have agreed to pay $10 million to the U.S. government to resolve allegations it fraudulently obtained federal funding.
The case, which involves three former Harvard stem cell researchers, dates back several years. In 2014, Circulation retracted a paper by Piero Anversa, Annarosa Leri, and Jan Kajstura, among others, amidst a university investigation into misconduct allegations. Anversa and Leri — whose lab was described as filled with “fear” by one former research fellow — later sued the hospital for notifying journals of that investigation. They lost.
In the agreement announced today by the Department of Justice (DOJ), Partners Healthcare and Brigham and Women’s Hospital have agreed to pay the government $10 million to settle allegations that the researchers fraudulently obtained funding from the National Institutes of Health:
When journals learn papers are problematic, how long does it take them to act?
We recently had a chance to find out as part of our continuing coverage of the case of Anil Jaiswal at the University of Maryland, who’s retracted 15 papers (including two new ones we recently identified), and has transitioned out of cancer research. Here’s what happened.
As part of a public records request related to the investigation, we received letters that the University of Maryland sent to 11 journals regarding 26 “compromised” papers co-authored by Jaiswal, four of which had been retracted by the time of the letter. The letters were dated between August and September 2016 (and one in February) — although, in some cases, the journals told us they received the letter later. Since that date, three journals have retracted nine papers and corrected another, waiting between four and six months to take action. One journal published an editorial note of concern within approximately two months after the university letter.
And six journals have not taken any public action.
Over the past few years, Christian Kreipke has been embroiled in legal battles with the Detroit VA Medical Center and Wayne State University, where he held a dual appointment. In 2010, Kreipke accused Wayne State of misusing federal funds — then was fired in 2012 when the university brought its own case of research misconduct against him. In 2013, the VA followed suit. In 2014, Kreipke lost a whistleblower lawsuit against the university. As a result of the Wayne State investigation, journals have retracted five of his papers, some as recently as last month.
In March, a judge ordered the Department of Veterans Affairs to reinstate Kreipke’s position, among other requests. Read the rest of this entry »
The troubles continue for a bone researcher, who’s lost multiple papers in recent months due to problems ranging from data issues to including authors without their consent.
Now, journals have retracted two more papers by Yoshihiro Sato. And in a sign of the downstream effects that fraud can have, another journal has retracted two meta-analyses by other authors that cited his work.
Earlier this month, the journal Current Medical Research and Opinion retracted the two meta-analyses because they were based on recently retracted papers by Sato, affiliated with Mitate Hospital. The two new retractions of Sato’s papers are a review and a randomized controlled trial.
Sato was not an author on the meta-analyses published in 2008 and 2011; he was, however, first and lead author on all the retracted papers referenced in the notices. The notices state that the trio of authors on the meta-analyses:
A researcher has threatened to sue publisher Taylor & Francis for mentioning a misconduct investigation into his work in a retraction notice.
According to the notice, the publisher retracted a 2008 paper and a book chapter after learning about a misconduct investigation into the work of Mark Jackson, a department head and endowed chair, respectively, at universities in Kansas.
Unfortunately, we don’t know much about the nature of the misconduct investigation; Jackson told us he initiated the retractions after raising concerns his colleagues had violated intellectual property. He has since told the publisher he would take legal action if it didn’t remove the phrase noting that the retractions stem from a misconduct investigation into his work from the notice.
Here’s the notice, issued by Materials Science and Technology:
PLOS ONE has retracted the last of five papers by a former employee of Pfizer, who the company fired after determining she had duplicated data.
After its investigation, Pfizer asked journals to retract five papers co-authored by Min-Jean Yin. Last week, PLOS ONE retracted the final two remaining papers. Both notices cite image duplications; Yin contacted the journal about one paper, but did not comment on the other retraction.
Here’s the notice for “miR-221 Promotes Tumorigenesis in Human Triple Negative Breast Cancer Cells:”
As third retraction for prominent physicist appears, university still won’t acknowledge investigation
Despite a university’s attempts to avoid discussing a misconduct investigation involving one of its former (and prominent) researchers, we keep reading more about it.
In the third retraction this year for physicist Dmitri Lapotko, the journal mentions a misconduct investigation at Rice University, which concluded the data had been falsified. Trouble is, whenever we’ve tried to talk to Rice about that investigation, they won’t even confirm it took place.
Here’s the retraction notice for “Transient Photothermal Spectra of Plasmonic Nanobubbles,” published by Langmuir:
A journal has retracted another paper by a graduate student formerly based at Albert Einstein College of Medicine in New York, after she spontaneously confessed to fabricating data.
As we reported in April 2016, principal investigator Florence Marlow alerted the institution’s Office of Research Integrity and two journals about Meredyth Forbes’s admission, prompting an investigation into the extent of the data manipulation.
Three papers were affected: In January 2016, Development flagged one paper with an expression of concern, alerting readers to the potential issues with the data while the authors and Research Integrity Office investigated the scope of the problem. In April 2016, another paper was retracted by Cell Reports; the third, also published in Development, received a correction.
A pharmacology journal has retracted a 2011 paper after concluding images in three figures had been manipulated.
According to the British Journal of Pharmacology, four of the five authors claim they played no role in the manipulation. There is no comment from the remaining author, first author Ian Morecroft, a research associate at the University of Glasgow.
Here’s more from the notice, which says an investigation at the University of Glasgow is ongoing:
After being accused of falsifying three figures in a submitted manuscript, Mauvais-Jarvis sued his accusers and officials at his former employer — Northwestern University — for defamation and conspiracy in 2011.
In 2014, a judge dismissed the suit. We wish we could tell you more details about it—such as what the university’s misconduct investigation found, or how the lawsuit was concluded—but they remain shrouded in mystery. What we know is based on court records from the lawsuit, which we recently obtained through an unrelated public records request. Even without all the details, it’s a long, sordid tale, involving a lot of finger-pointing and allegations of misconduct.
In 2008, a former research technician in the lab of Mauvais-Jarvis, then an associate professor of medicine at Northwestern University, raised concerns of fabrication in two figures in a paper on the regulation of insulin synthesis that had been submitted the Journal of Biological Chemistry. An inquiry committee at the university unanimously concluded that research misconduct charges against Mauvais-Jarvis were not credible.
But then a third figure in the manuscript was found to be “inaccurate,” and the university initiated a second inquiry. That’s when Mauvais-Jarvis — whose papers have been cited more than 2,000 times, according to Clarivate Analytics’ Web of Science, formerly part of Thomson Reuters — initiated a lawsuit. Read the rest of this entry »